Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amplimmune Inc.

Division of AstraZeneca PLC
www.amplimmune.com

Latest From American Cyanamid Co.

Watson Becomes Actavis: Name Change To Reflect Greater International Focus

Watson’s merger with Actavis will create the world’s third-largest generic drug company, to be known as Actavis, with significant ex-U.S. market share, especially in the U.K., Nordic countries and Russia.

BioPharmaceutical North America

Watson/Actavis: Name Is Just One Of Many Changes Resulting From Merger Completion

With the Actavis deal finalized, Watson achieves its long-sought goal of becoming a major international player in generics, and announces a new global management team to undertake the critical component: execution.

BioPharmaceutical North America

ANDA Graveyard: FDA Begins Weeding Out Inactive Generic Applications

The agency issued a list of 364 ANDAs that will be deemed withdrawn unless the sponsor tells FDA it wishes to pursue them; it is a first step in clearing the backlog before generic drug user fees are enacted.

BioPharmaceutical United States

Wyeth: Trouble's Teachings

Recent news that long-term hormone-replacement therapy was doing more harm than good slashed Wyeth's valuation by 25%-$15 billion-overnight, even though the company maintains there was "nothing shocking" in the study. Hormones had been its top-selling product franchise. It's another hard knock for a company that only just settled a nationwide class-action suit, to the tune of $13.2 billion, over anti-obesity drugs fen-phen and Redux. Wyeth has also had well-publicized troubles with manufacturing. But Wyeth is stronger than it was just a few years ago, partly because acquisitions boosted research productivity but also because it learned from hardship. The company is quicker to face up to problems and deal with them. It's also more aware of the ramifications of developing biological drugs, especially in terms of production. Wyeth should be able to continue growing without resorting to M&A, if it can learn to be as active in prosperity as it has learned to be through adversity.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • AstraZeneca PLC
  • Senior Management
  • Michael Richman, Pres. & CEO
    Sol Langerman, PhD, SVP, CSO
    Gary Fanger, PhD, SVP, COO
  • Contact Info
  • Amplimmune Inc.
    Phone: (301) 309-9800
    45 West Watkins Mill Rd.
    Gaithersburg, MD 20878
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register